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Abstract: 
Background: Sickle cell anaemia (SCA) is a hereditary blood disorder caused by a single mutation in the haemoglobin gene. The 
disease burden of  SCA is highest in Nigeria. The allele specific polymerase chain reaction (ASPCR) method is applicable for the 
direct detection of  known single nucleotide polymorphisms (SNPs). 
Objective: To investigate the use of  the single tube ASPCR as an accurate and affordable method for SCA screening in Nigeria. 
Methods: DNA was extracted from study subjects with normal haemoglobin, HbAA (20), sickle cell anaemia, HbSS (20) and 
carriers, HbAS (1). Haemoglobin was genotyped by ASPCR using two primer sets that amplifies the wildtype and mutant hae-
moglobins in each sample. Amplicon sizes were analyzed by gel electrophoresis. 
Results: Amplicons were visible after electrophoresis at regions 517 base pair (bp) for HbA and 267 bp for HbS. ASPCR cor-
rectly and unambiguously detected the presence or absence of  haemoglobins A and S from all samples collected, demonstrating 
its accuracy and precision for the screening of  SCA. 
Conclusion: This study validates ASPCR as an effective, low cost approach for the clinical screening of  SCA in Nigeria. ASPCR 
is also applicable for other genetic diseases, paternity testing, and forensics where more expensive fluorescence-based approach-
es are not obtainable.
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Sickle cell anaemia (SCA) is a chronic blood disorder 
initiated by inheriting a faulty (sickle) haemoglobin with 
chronic haemolytic anaemia and recurrent vaso-occlusion 
as its key pathological features1,2. The molecular explana-
tion of  the sickle hemoglobin is a single nucleotide poly-
morphism (SNP) or point mutation (GAG → GTG) in 
the β-haemoglobin gene (HBB). The homozygosity for 
the mutated S haemoglobin (HbS) leads to a substitution 
of  a hydrophobic valine amino acid for the normal hydro-
philic glutamic acid residue at the sixth amino acid of  the 
β-globin chain (glu6val) and the resulting HbS β-globin 
chains are substituted for normal HbA β-globin chains3,4. 
This single-point mutation is associated with complex 
genetic interactions evident by the multiple phenotypic 
expressions and disease modifiers that are not well under-
stood5,6. The clinical heterogeneity of  SCA varies widely 
from a mild clinical course to very severe complications 
with significant organ damage and early mortality7,8. Hae-
moglobin A also termed the wild type haemoglobin, is the 
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normal adult form of  haemoglobin and its homozygosity 
(HbAA) indicates the normal genotype while heterozy-
gosity (HbAS) denotes a carrier status but individuals do 
not have symptoms.
Sickle cell anaemia is predominant in Africa, the Middle 
East and Mediterranean axis, the Indian sub-continent, 
the Caribbean and South America. Sub-Saharan Africa 
records the highest burden and incidence of  SCA. Annu-
ally over 250,000 affected babies are born in this region, 
representing 1–2% of  new-borns in some countries9,10. In 
Nigeria alone, about 25-30% of  the population are trait 
carriers and SCA occurs in approximately 2% of  all births 
representing over 150,000 babies born yearly with the dis-
ease11,12. 
In Nigeria, current diagnosis and management of  SCA 
is still sub-optimal. Screening is limited to the sickling 
solubility test and haemoglobin electrophoresis. Sickling 
solubility test can detect the presence of  haemoglobin S, 
but these tests cannot distinguish SCA from sickle cell 
trait (SCT)13. Haemoglobin electrophoresis is a useful 
screening method that can determine the phenotype of  
SCA but is not a reliable method for the determination of  
genotype in infants less than 6 months since high levels 
of  fetal haemoglobin (haemoglobin F) that persists from 
birth is the predominant haemoglobin at this age. Thus 
haemoglobin electrophoresis is not suitable for prenatal 
and neonatal screening14. 
More accurate methods like thin-layer isoelectric focus-
ing (IEF) or high performance liquid chromatography 
(HPLC) are rare in Nigeria. Molecular methods for the 
SCA diagnosis are not common due to the paucity of  
skilled personnel. In addition molecular laboratories are 
few and mostly sequestered in federal institutions. In this 
study, the single tube ASPCR genotyping of  SCA as a low 
cost method of  molecular diagnosis of  SCA in develop-
ing countries was investigated. 
Materials and methods
Study sites and patient recruitment: Study subjects 
were recruited from Lagos State in Nigeria. A total of  41 
participants were pooled from two clinics. Twenty (20) 
sickle cell anaemia (HbSS) subjects were recruited from 
the Haematology Unit, Lagos State University Teaching 
Hospital, while twenty (20) non-carriers (HbAA) and one 
(1) trait carrier (HbAS) were recruited from the Health 
Centre, University of  Lagos Akoka Yaba, Lagos State. A 
questionnaire was administered and participants were en-
rolled after signing the consent forms approved by the 
Ethics Committees.
Sample collection: 5ml of  whole blood from each pa-
tient was collected into EDTA tubes. Blood samples were 
stored in ice coolers and transported to the postgraduate 
laboratory at the Department of  Cell Biology and Genet-
ics, Faculty of  Science, University of  Lagos for genetic 
analysis. 
DNA extraction: The DNA extraction was carried out 
using E.Z.N.A. Blood DNA Mini Kit Omega Biotek 
USA following the outlined protocol.
DNA quality and quantity: DNA quality and quantity was 
measured using an ultraviolet (UV) spectrophotometer at 
260nm and 280nm wavelength.  
Bi-directional Allele Specific Amplification:  The gen-
otype results obtained from patient files of  all volunteers 
enrolled for this study was confirmed by abi-directional 
allele specific amplification ASPCR method described by 
Waterfall and Cobb (2001). Primer sequences to detect 
the wild-type and mutant alleles are as follows: 
WT-AS (5′-ATG GTG CAC CTG ACT CCT GA-3′) and 
WT-CP517 (5′-CCC CTT CCT ATG ACA TGA ACT-3′) 
for amplification of  a 517 bp fragment from the normal 
β-globin gene (wild-type primer set). 
MUT-AS (5′-CAG TAA CGG CAG ACT TCT CCA-3′) 
and MUT-CP267 (5′-GGG TTT GAA GTC CAA CTC 
CTA-3′) for amplification of  a 267 bp fragment from 
homozygous mutant DNA confiming sickle cell disease 
(mutant primer set). 
Amplification was performed using a Thermos Scientif-
ic Arktik Thermal Cycler (Thermo Fisher Scientific Oy, 
Finland) through an initial denaturation at 95°C for 2 
min, followed by 30 cycles of  denaturation at 95°C for 
30s, primer annealing at 60°C for 30s, extension at 72°C 
for 35s and a final extension at 72°C for 10 mins.
Analysis of  pcr products
An aliquot (10µl) of  each PCR product was loaded with 
6× loading dye buffer (Promega) onto a 2% agarose gel 
stained with Red Safe (Molecular Probes, UK) and run in 
0.5X tris borate EDTA (TBE) buffer at 75volts for 1 hr. 
Amplification products were visualised by UV transillu-
mination (305 nM). The sizes of  expected amplicons, 517 
bp indicating the presence of  the normal β-globin gene 
(HBA/A) and 267 bp indicating presence of  the mutant 
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gene (HbS/S) were read against the 100 bp DNA molec-
ular weight ladder and genotype results were obtained. 
Ethical approval
Ethical approvals obtained for this study are from Uni-
versity of  Lagos Teaching Hospital (LUTH) HREC 
with approval number (LREC/10/86/479) and Lagos 
State University Teaching Hospital (LASUTH) Research 





The primers used in this study are designed to amplify 
both mutant and wild-type alleles present in a single re-
action tube. To achieve this, a wild-type primer (WT-AS) 
which is complimentary to the non-coding strand of  the 
wild-type allele, is designed to terminate at the polymor-
phic site where the mutation occurs. In the presence of  
this primer, only wild-type DNA will extend. The mutant 
primer (MUT-AS) on the other hand is complimentary to 
the coding strand of  a mutant allele, it terminates at the 
SNP site where the mutation (A T) has occurred and will 
extend only in the presence of  a mutant allele. In order to 
achieve molecular conformation, two outer primers WT-
CP517and MUT-CP267 are placed at a predefined num-
ber of  bases on the opposite strands of  the allele specific 
pair.  Figure 1 shows an illustration of  the bi-directional 
ASPCR as described by Waterfall and Cobb 2001.
Figure 1. An illustration of the bi-directional ASPCR as described by Waterfall and Cobb 2001. The wild-type primer set (WT-
AS/WT-CP517) is shown in blue and mutant primer set (MUT-AS/ MUT-CP267) is in purple.
A –Illustrates that purple amplicons are formed only when the mutant primers are extended and
B- Illustrates that blue amplicons are formed only when the wild-type primers are extended.
The presence of both mutant and wildtype amplicons identifies the heterozygous individual.
A
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Optimization of  the sickle cell anaemia ASPCR con-
ditions
Reaction conditions were optimised by altering the mag-
nesium chloride (MgCl2) concentration in the PCR mas-
ter- mix and the input DNA template on samples that 
were positive for HbAA, HbSS and HbAS.  Table 1. 
Shows optimized conditions arrived at in this study for 
the ASPCR.
Table 1. Optimized concentration of reactants in PCR master-mix 




MgCl2 dNTPs DNA 
template 
Concentration 0.8µM 0.8µM 1.5mM 80 µM 4ng 
 
Optimization results, indicate that up to 4ng of  DNA 
template and 1.5mM MgCl2 concentrations increased am-
plicon yield especially of  the wild-type amplicon. Higher 
MgCl2 concentrations did not have much effect on prod-
uct yield. Figure 2.
Figure 1. An illustration of the bi-direct ional ASPCR as described by Waterfall and Cobb
2001.
The wild-type primer set (WT-AS/WT-CP517) is shown in blue and mutant primer set
(MUT-AS/ MUT-CP267) is in purple.
A –Illustrates that purple amplicons are formed only when the mutant primers are extended
and
B- Illustrates that blue amplicons are formed only when the wild-type primers are extended.
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Genotyping results
A total of  41 subjects participated in this study; 20 HbSS 
(13 female and 7 male) with; 20 HbAA (5 females and 
15 males) and 1 trait carrier HbAS (female).  Amplifica-
tion results of  all homozygous (HbSS) patients revealed 
amplicon sizes at 267 bp only and heterozygous (HbAS) 
revealed amplicons at both 267 and 517 bp (Fig.3a), while 
healthy individuals’ (HbAA) revealed amplicon sizes at 
517 bp only (Fig. 3b). 
2A
2B
2C Figure 2. Gel electrophoresis after optimization of reactants
2A- Gel electrophoresis results with 2ng DNA and 1mM MgCl2
2B- Gel electrophoresis results with 4ng DNA template and 1.5mM MgCl2
2C- Gel electrophoresis results with 4ng DNA template and 2.5mM MgCl2
M- Molecular ladder, C-negative control, SS- reactions with HbSS DNA
template, AS- reactions with HbAS DNA template, AA- reactions with HbAA
DNAtemplate
M    C     SS   SS SS SS SS SS SS
M    C     SS   SS SS SS SS SS SS






Fig 3. Gel electrophoresis of PCR amplifications. 
M-100bp Molecular marker and C- negative control. 
Set 3A- lanes 3, 5, 6, 7 and 8 are reactions with mutant DNA template (HbSS), lane 6 represents a reaction 
with both alleles (HbAS) and lane 10 is reaction with wild-type (HbAA). 
Set 3B- lanes 3, 5, 6, 7, 8, 9 and 10 are reactions with wild-type (HbAA).
M       C      SS               SS AS    SS      SS SS AA 
3A 3B
M     C       AA             AA AA AA AA AA AA
517bp517bp
267bp
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from patients records 
Alleles detected by 
ASPCR 
Percentage match 
20 Hb SS Hb SS 100% 
20 Hb AA Hb AA 100% 
1 Hb AS Hb AS 100% 
 
According to participants’ clinical records, all patients 
were genotyped using the alkaline haemoglobin electro-
phoresis method. The results of  Hb electrophoresis and 
ASPCR based single tube genotyping were in full agree-
ment for the sickle cell trait, sickle cell individuals and the 
healthy controls (Table 2). 
Discussion
This study investigated the use of  ASPCR in screen-
ing/diagnosing SCA in a Nigerian setting. This method 
is adapted from the allele specific amplification (ASA) 
methods. With ASPCR, the bi-directional nature of  prim-
ers enable the use of  a single tube for the diagnosis of  a 
two allele system15. The results indicate that, ASPCR can 
be used for screening both for healthy, SCT and SCA. 
Furthermore, the use of  a single tube to detect variant 
haemoglobin alleles present in each patient sample proj-
ects this technique as potentially fast and affordable by 
reducing the use of  scarce PCR master-mixes, consum-
ables and other reagents. Akanni et al.14 reportedly em-
ployed the ASPCR method in their study however their 
approach differed by the use of  conventional separate 
tubes and separate PCR master-mixes each requiring dif-
ferent primers to amplify the different haemoglobin types 
present per patient sample. 
Thin-layer isoelectric focusing (IEF) and high perfor-
mance liquid chromatography (HPLC) are routine tech-
niques employed in the accurate diagnosis of  SCA in 
more developed countries. Challenges that have limited 
the use of  these up-to-date methods in Nigeria include 
the huge cost of  equipment acquisition, additional costs 
of  consumables and regular equipment maintenance. A 
recent survey carried out by the Nigerian Sickle Cell Dis-
ease Network (NSCDN) on the available facilities and the 
prevalent management practices in SCD clinics in Nige-
ria revealed that the haemoglobin electrophoresis method 
is commonly used for screening and diagnosis of  SCA; 
In addition, only three teaching Hospitals in Nigeria had 
HPLC machines installed but were not routinely used, 
and none had IEF facilities 2 (Galadanci et al2. The quest 
for more affordable approach to accurately screen or di-
agnose SCA in Nigeria is of  serious concern. 
Several molecular methods for diagnosis of  haemoglobin 
disorders have been described. The availability of  addi-
tional equipment such as sequencers and fluorescence 
detectable devices will affect the method of  choice.16 
Methods such as ASPCR and PCR- restriction fragment 
length polymorphism (RFLP) may offer an affordable al-
ternative to HPLC and IEF in Nigeria as it provides the 
ability to detect alleles of  the different globin genes di-
rectly, and if  necessary results can be confirmed via oth-
er methodology like DNA sequencing. These molecular 
methods are also suitable for new-born sickle cell screen-
ing programs as they offer several potential advantages, 
such as greater reliability, specimen stability, and amena-
bility to automation and large-scale screening. 
While the cost of  haemoglobin electrophoresis ($3-$4) re-
mains the most affordable method of  screening for SCA, 
it is saddled with limitations and still requires additional 
tests for accurate diagnosis. The cost of  SCA screening 
using HPLC in a government laboratory in Lagos Nigeria 
is estimated at $50 to $60 per test. In such laboratories 
where HPLC test is done, the charge for haemoglobin 
electrophoresis is absorbed in the cost for HPLC test. 
Besides the initial set up costs for molecular laboratory, 
screening using molecular methods will vary with the ap-
proach and can range from $25 to $70 per test or more if  
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sequencing of  fragment DNA is desired. The single tube 
ASPCR method is estimated at $20 to $25 per test based 
on our study. The cost of  IEF techniques in Nigeria is 
not known at the time of  this study probably due to its 
non-availability. 
Improving SCA diagnosis in Nigeria and sub-Saharan Af-
rica is very vital in reducing the mortality levels attributed 
to SCA.  It is well reported that most deaths from SCA 
in Africa occur before the diagnosis is ever made. Many 
children and sometimes adults die of  pneumonia, bacte-
rial sepsis, and acute anaemia without identifying SCA as 
the critical underlying cause of  death. Lack of  early and 
accurate diagnosis also makes it difficult to proffer ade-
quate interventions and treatment for children whose true 
underlying disease remains unknown13. Similarly, many 
adults are not aware of  their accurate sickle cell status. 
In a study by Burnham-Marusich et al17 in South-Eastern 
Nigeria, about half  of  parental self-reports on sickle cell 
status or genotypes status were wrongly reported while 
enrolling for the study. This calls for an urgent need and 
approach to accurately diagnose the sickle cell status of  
adults or entire families in the Nigerian population. In-
troducing the ASPCR method in the Nigerian will signifi-
cantly increase the awareness of  adult accurate sickle cell 
status and be of  great benefit to couples before getting 
married or starting families. This will further reduce the 
population of  new-borns affected with sickle cell anae-
mia in Nigeria.
Conclusion
As many research and clinical laboratories in Nigeria em-
brace the use of  molecular biology techniques, it is hoped 
that early and accurate diagnosis of  sickle cell anaemia be-
comes easily accessible. The ASPCR method is also appli-
cable for other genetic diseases, paternity testing, forensic 
and pharmacogenomic research where more expensive 
fluorescence-based approaches are not obtainable.
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